secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009697
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed secures $50M upfront private placement; warrants could add $99.4M; funds Phase 2b DLB trial
--------------------------------------------------------------------------------

- Gross proceeds ~$50M upfront; up to ~$149.4M if Series A warrants ($39.24/share, 100% premium) fully exercised.
- Unit price $19.745; includes pre-funded warrants ($0.001 strike) and Series A warrants expiring Apr 2027 or post positive Phase 2b data.
- Financing led by RA Capital Management with Armistice, Special Situations, Soleus; Morgan Stanley and Canaccord placement agents.
- Net proceeds to fund neflamapimod R&D for dementia with Lewy bodies; expected cash runway through end of 2025.
- Closing expected April 1, 2024; resale registration statement to be filed within 60 days after close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/crvo20240326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer